Get started
Alibaba (BABA) is going down ?Market Broader China Tech – CQQQ – Tracks a wide range of Chinese technology companies. Large-cap China exposure – FXI – Focuses on major Chinese companies, including Alibaba. Stock: Alibaba (BABA) The stock has recently fallen below its 50-day moving average, indicating short-term weakness. The 10-day moving average has crossed below the 20-day, a short-term bearish signal. MACD is starting to reflect bearish momentum, suggesting growing market fear. Selling volume has increased, confirming downward pressure from investors. Fundamentals & Outlook Despite recent technical weakness, Alibaba remains fundamentally undervalued relative to its peers and historical metrics. The company continues to generate strong free cash flow and maintains a healthy balance sheet. However, broader market sentiment around Chinese tech remains cautious due to regulatory overhang and global macro factors. Conclusion Near-term pullback is possible due to bearish technical indicators and weak sentiment. Long-term investors may view this as a potential accumulation zone, provided there's risk tolerance for volatility in the China tech sector.
NYSE:BABAShort
by Missmoyeu
AMD Break-out above this level means new ATH at $300.Advanced Micro Devices (AMD) is on a recovery attempt following the April 07 2025 bottom, which is technically a Higher Low on the 3.5-year Channel Up. This week it broke above the first Resistance level of this attempt, the 1W MA200 (orange trend-line), which is key as it had 2 rejections since February 18 2025. However the biggest Resistance test is right above it and consists of a strong Cluster of the 1D MA200 (green trend-line), the 1W MA50 (blue trend-line) and the Lower Highs trend-line from the All Time High (ATH). The previous Bullish Leg of the Channel Up (started on October 10 2022), consolidated for 1 month once it broke above this Resistance Cluster (blue circle) and then marched towards the pattern's Higher High, which was naturally a Higher High. The similarities between the Legs are striking, the Bearish Legs (both declined by -66.86%) were confirmed by 1W MACD Bearish Cross and the Bullish Legs by a Bullish Cross, which the 1W MACD just completed last week. This is a major confirmation and technically the earliest for a long-term Buy. Assuming again that the symmetry will continue to hold on this emerging Bullish Leg, we can expect it rise by +318.17% as well. Based on that, our long-term Target on AMD is $300. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:AMDLong
by TradingShot
1
Possible Targets for Nvidia on Both Upside and DownsideNvidia has surged more than 55% since the early April dip and over 40% from the second dip, as expected in our earlier post. This massive rally was supported by a softening in trade policy (Bloomberg trade uncertainty index fell to 7.67 from 16.27), Nvidia's valuation being well below historical averages, and momentum sparked by Trump’s Middle East business trip. Despite the surge, Nvidia still trades below its historical average based on forward price-to-earnings ratios. The stock has averaged a forward P/E of 32.2x over the past year, 34.2x over the last two years, and 40.2x over the past five years. Its current forward P/E stands at 28.4x. If Nvidia were to return to these averages, the implied price would be: 1-year average (32.2x): $153.04 2-year average (34.2x): $162.20 5-year average (40.2x): $190.79 However, relying on the 5-year average may not be ideal, as Nvidia’s explosive growth potential is no longer at the same trajectory it was five years ago. The 1-year average at $153.04 could be a more realistic near-term target. Around the 1-year p/e price target, Nvidia has also a notable technical resistance. The stock has an infamous double top at $154 that has capped price advances twice before in November and January. This suggests that a short-term bet on further upside could be risky. If Nvidia pulls back to around 120 level, however, it may offer a good buying opportunity, with upside potential toward 150 or higher, depending on the broader macroeconomic conditions at the time. Please also check our earlier post:
NASDAQ:NVDA
by ftdsystem
SRx Health (SRXH): Financial Analysis and Merger with BTTRPre-Merger Financial Overview (Better Choice Company) Better Choice Company Inc. – renamed SRx Health Solutions Inc. prior to the merger – focused on pet nutrition and wellness products (Halo brand). In 2024, the company reported net revenues of $34.97 million, down from $38.59 million in 2023. Despite the decline in revenue (-9%), gross profitability improved: gross margin rose to 37% in 2024, with gross profit of ~$12.99 million (compared to 30% in 2023, gross profit ~$11.80 million). The drastic reduction in operating costs ($18.96 million in 2024 vs. $32.98 million in 2023) has significantly reduced operating losses. In fact, the net loss for the 2024 financial year was almost eliminated at $0.17 million (compared to a heavy loss of $22.77 million in 2023). This reversal is partly due to extraordinary items: in 2024, Better Choice recorded a gain of $6.2 million from the extinguishment of debts and liabilities, in addition to avoiding goodwill impairment charges that had weighed on the balance sheet by ~$8.5 million in 2023. On an adjusted basis, 2024 adjusted EBITDA remained negative at approximately $1.9 million, but was a significant improvement (≈78% lower) compared to the EBITDA loss of approximately $8.6 million in the previous year. Earnings per share (EPS) also decreased from $(32.29)$ to $(0.10)$ due to lower liabilities and an increase in the average number of shares (from ~705,000 to ~1.615 million after reverse stock splits and new issuances). As of December 31, 2024, the company had $3.1 million in cash and had used approximately $2.4 million of its revolving credit facility (limited remaining capacity). Working capital was positive (~$7.9 million at the end of 2024, according to management) thanks to the reduction in short-term debt during the year. Overall, Better Choice showed signs of a turnaround in 2024: declining revenue but an improved channel mix (closure of the unprofitable direct-to-consumer channel), growing gross margins, and costs under control, with four consecutive quarters of gross margin improvement and three consecutive quarters of reduced losses. SRx Health Solutions (Canada) Pre-Merger Data SRx Health Solutions Inc. – the company acquired by Better Choice – is an integrated specialty healthcare services provider in Canada with a different but complementary business model. Prior to the merger, SRx operated one of Canada's largest specialty pharmacy networks, with 35 active pharmacies, 40 specialty infusion clinics, 4 clinical trial centers, and 2 pharmaceutical distribution centers. This platform enabled it to generate annual revenues of C$161.5 million in 2023, with adjusted EBITDA of C$11.4 million (IFRS). These volumes correspond to approximately $120 million in revenue and ~$8.5 million in EBITDA on a pro forma basis in US dollars, indicating operating profitability of around 7% on revenue. Better Choice management highlighted that SRx has shown consistent revenue and cash flow growth in recent years, building its network from 2013 to the present. According to the announcement, SRx has achieved steady growth and positive margins by focusing on high-value segments (specialty drugs and therapies) under the leadership of founder and CEO Adesh Vora, a pharmacist with 24 years of experience in the healthcare industry. It should be noted that SRx's financial statements were prepared in accordance with IFRS and are being converted to US GAAP post-merger; accounting differences may arise, but the pro-forma figures provided give an order of magnitude of SRx's pre-acquisition operations. In summary, prior to the merger, SRx Health was a larger business than Better Choice in terms of revenue (approximately four times larger) and had positive margins, operating in a market—the Canadian specialty pharma market—estimated to be growing strongly (∼11% CAGR through 2030). This context motivated the merger of the two companies, combining SRx's solid recurring revenue base with Better Choice's pet activities. Better Choice – SRx Health Merger: Strategic Motivations and Synergies The merger between Better Choice and SRx Health Solutions, announced in September 2024 and completed in April 2025, was presented as a transformative strategic operation. The stated goal is to create a leading global health and wellness company across multiple sectors, offering products and solutions for pets, people, and families in a single integrated group. In practice, the new SRx Health Solutions Inc. combines the pet health & nutrition sector (pet food and wellness products, Halo brand) with the specialty healthcare sector for human patients (specialty pharmacies, clinics, and advanced healthcare services). This diversification aims to capitalize on converging trends: on the one hand, the growing “humanization” of pets and consumer focus on pet health (Better Choice's core business), and on the other, the increasing demand for specialty therapies, highly complex drugs, and personalized healthcare services in Canada (SRx's core business). Michael Young, Chairman of Better Choice, described the transaction as “a transformative opportunity that positions Better Choice as a global leader in the health and wellness industry.” He praised the SRx team's work in building their healthcare network and highlighted that, once combined, there are immediate operational and growth synergies estimated at over $1.7 million that the group expects to realize quickly. These synergies are expected to come from the integration of infrastructure and distribution networks, as well as the implementation of cross-growth strategies between the two entities. For example, SRx could support the distribution of Halo products in new markets (Canada and pharmaceutical channels) and, conversely, Better Choice could introduce SRx services/solutions in the US market or online, leveraging its digital presence. In addition, the merger strengthens the capital structure: Better Choice, which was a micro-cap with limited resources, gains a larger, more capitalized business, while SRx gains access to the US capital market through its NYSE American listing (without going through a traditional IPO). From an organizational standpoint, SRx founder Adesh A. Vora will assume the role of CEO of the new SRx Health Solutions Inc., bringing his extensive experience in the pharmacy sector, while former Better Choice CEO Kent Cunningham will lead the Halo (pet) business unit within the group. The combined board of directors includes five members from both companies to balance expertise (Vora is also appointed Chairman). In summary, the strategic rationale for the merger lies in the creation of a 360° wellness player with complementary assets and cross-selling opportunities, capable of competing in both the premium pet and specialized healthcare markets. The transaction was approved by a large majority of Better Choice shareholders in March 2025 (over 71% of voting shares, with authorization to issue ~30 million new shares for the acquisition), a sign of confidence in the prospects outlined by management. Synergies and prospects: According to official statements, the new combined group has a significantly strengthened financial profile. On a pro-forma basis, in the first six months of 2024, the two companies would have totaled ~$95 million in combined revenues. Projections for 2025 indicate combined revenues of over $270 million and EBITDA of over $10 million, a significant jump from Better Choice's historical standalone figures. If achieved, these targets would imply significant growth driven by the contribution of SRx (which alone would account for the majority of revenues) and the launch of joint initiatives. The prospective EBITDA margin would still be around 4% of revenues, indicating that management is primarily focused on expanding business volume while maintaining modest margins, likely due to growing investments and integration. Initial cost synergies ($1.7 million) could slightly improve profitability in the short term, while further growth synergies (e.g., pet/pharma cross-selling, geographic expansion) could impact sales and margins in the medium term. On the operational side, SRx brings expertise in the regulated healthcare sector, relationships with public authorities (e.g., healthcare reimbursements in Canada), and a technology and logistics-distribution platform for specialty drugs. Better Choice contributes an established consumer brand in holistic pet food and developed international e-commerce and retail channels (Amazon, Chewy, distribution in Asia, etc., as evidenced by APAC growth of +9% in 2024). SRx Health Solutions' new stated mission is to “become the most innovative wellness company” by investing in product innovation and digital initiatives to simplify access to care (as per the May 2025 investor presentation). The merger also involves a corporate name change: as of April 30, 2025, Better Choice officially assumed the name SRx Health Solutions Inc. and its stock ticker changed from “BTTR” to “SRXH,” reflecting its new multi-sector focus. In parallel, the company has taken steps to strengthen its financial structure: concurrently with the closing, a $8.8 million private placement was completed with an institutional investor at a price of $2.18 per share (above the last previous market price). This investment provided immediate liquidity of approximately $8 million (before expenses) and signals of confidence from new shareholders. In addition, SRx Health (the Canadian part) had improved its financial standing by previously converting $4 million of debt into equity (a transaction announced in early 2024) in order to enter the merger with strengthened working capital. Overall, therefore, the transaction was motivated by industrial logic of diversification and scale, supported by financial considerations (capital strengthening and access to capital) and well received at the shareholders' meeting. The effective integration of the businesses and the realization of the promised synergies now remain to be accomplished, in a market environment that presents growth opportunities (expanding pet and specialty pharma sectors) but also significant competitive challenges. Competitive Comparison and Industry Benchmark From an industry perspective, SRx Health Solutions Inc. is an atypical entity in that it operates in both the Healthcare sector (pharmacies, clinics, healthcare services) and the Consumer Pet Care sector. Officially, the company is classified in the healthcare sector (under “Drug Manufacturers/General,” although distribution and services are its main activities). It is therefore useful to assess SRXH's position in relation to two competitive areas: competitors in the human health market (specialty pharma/health services) and players in the pet food/wellness market. Specialty pharmacy/healthcare services sector: In Canada, the specialty pharmacy market is fragmented but has large players such as the specialty divisions of Shoppers Drug Mart (Loblaw) and the McKesson Canada network, as well as independent operators. With ~$120 million in revenues (pro-forma 2023), SRx is a small-to-medium-sized operator compared to national leaders, but is one of the few with a widespread presence in all 10 Canadian provinces. Its focus on highly complex drugs and infusions places it in a niche with relatively high barriers to entry (given the need for clinical expertise, special licenses, and cold chain logistics management for biological drugs, etc.). The Canadian specialty drug market is rapidly expanding (valued at ~$7.4 billion US$ in 2024, expected to reach ~$13.9 billion by 2030), which provides SRx with a favorable tailwind for organic growth. In terms of profitability, more mature players in the healthcare sector often report double-digit EBITDA margins; SRxH forecasts an EBITDA margin of ~3-4% for 2025, indicating that there is room for improvement as operations are integrated and economies of scale are realized. Compared to healthcare industry financial benchmarks, SRx currently has low net margins (historically, Better Choice was loss-making and SRx Canada presumably had modest net profits) and low capitalization, factors that could be weaknesses when compared to giants such as CVS Health, Walgreens, or even Canadian chains backed by large groups, which enjoy ample financial resources and lower capital costs. On the other hand, SRx may have the flexibility of a more agile player dedicated exclusively to the specialist segment, without the legacy of generalist retail networks; its vertical integration (clinics + pharmacy + clinical trials) is a distinctive feature compared to many competitors focused solely on drug distribution. Pet food & wellness sector: SRxH's Halo business unit operates in the premium pet food market, competing with established brands such as Blue Buffalo (General Mills), Royal Canin (Mars), Hill's (Colgate-Palmolive) and other natural/holistic brands. This is a highly competitive but growing market, driven by premiumization and higher per capita spending on pets. With ~$35 million in annual revenue, Halo is small compared to global leaders (just think that the pet care divisions of giants such as Nestlé and Mars have revenues in the tens of billions). Even compared to focused rivals such as Petco Health & Wellness (WOOF) – a US chain that has integrated retail and veterinary services – Halo is small (Petco has annual revenues of ≈$4 billion). However, Halo has built a loyal niche in the holistic/vegan segment and benefits from a strong presence in e-commerce (Amazon, Chewy), where it has recorded significant growth (+32% on Chewy/Amazon in Q4 2024). The competitive challenge in pet food is mainly distribution (shelf space in pet and grocery chains) and marketing to differentiate the brand – areas where the injection of capital and greater visibility as part of SRxH could help. A potential competitive advantage for SRxH is its integrated “family-pet” offering: few operators can address the well-being of people and their animals at the same time. This innovative approach could attract a segment of consumers who are sensitive to holistic solutions for the whole family (e.g., health programs involving both human and animal patients). However, it is equally true that unified brand communication will need to avoid confusion: SRx Health will need to clearly explain its multi-business identity so as not to dilute the Halo brand equity in pet shops or SRx's credibility with clinicians and patients. Relative Strengths and Weaknesses. Below I summarize the main competitive strengths and weaknesses of SRx Health Solutions Inc. in the sector context: Strengths Complementary Diversification: Integrated business on two growing fronts – specialty healthcare and pet wellness – with cross-selling opportunities and mitigation of sector risks. Position in Expanding Markets: Presence in the Canadian specialty pharma market (CAGR ~11%) and premium pet care (global growth trend thanks to pet humanization). Extensive Operating Network: SRx's infrastructure of 35 pharmacies and 40 clinics across Canada – difficult for competitors to replicate quickly – combined with an international digital and distribution platform for pets. Improved Operating Performance: Better Choice's recent track record of improving margins and reducing losses, indicating the effectiveness of restructuring initiatives; SRx already profitable at the operating level (positive EBITDA) prior to the merger. Management and Expertise: Management team enriched by Adesh Vora's 20 years of experience in the pharmacy sector and Better Choice's expertise in pet digital marketing; renewed governance with representatives from both sides of the business. Refinanced Financial Structure: Reduction of Better Choice's legacy debt (extinction of $6.2 million in debt in 2024) and new capital raised ($8.8 million) providing liquidity for investment and growth, improving the financial profile in the short term. Weaknesses: Small Size vs. Big Players: Pro-forma revenue of ~$120 million represents a marginal share in the target markets (<<1%); smaller scale means less bargaining power with suppliers and lower economies of scale compared to giants such as CVS, Nestlé Purina, Mars, etc. Low Profitability and History of Losses: Expected EBITDA margin of ~4%, well below the industry average; net margin has been negative or slim to date. The new group's profitability is yet to be established and integration could initially generate costs. High Dilution and Low Capitalization: The transaction diluted the original shareholders (85% of the new company belongs to SRx shareholders) and the free float remains limited. With a market cap of only ~$15–20M, SRXH risks low visibility among institutional investors, high volatility, and difficulty raising additional capital in the stock market. Complexity of Integration: Merging a US pet retail/CPG company with a Canadian healthcare services company poses operational, cultural, and regulatory challenges. Synergies are not guaranteed if the two divisions remain too distinct; IT integration, logistics, and coordination of very different teams will be necessary. Focus and Brand Clarity: Risk of strategic dispersion: covering both the veterinary/pet and human healthcare sectors simultaneously could make it difficult to communicate a clear identity. Rebranding could confuse customers (e.g., veterinarians vs. doctors vs. pet consumers) if not managed carefully. Regulatory and Local Market Risks: The healthcare business is concentrated in Canada, subject to stringent regulation and dependent on public reimbursements; any policy changes could impact SRx. The pet segment operates in a highly competitive consumer market that is sensitive to pet owner preferences (where very large brands invest heavily in marketing). Any contraction in discretionary spending (e.g., recession) could affect premium pet sales. Conclusions : SRx Health Solutions (SRXH) emerges from the merger as a renewed and multifaceted company with financial indicators that differ significantly from Better Choice's past. Pre-merger financial data highlights Better Choice's turnaround in 2024 (drastic reduction in losses, improved adjusted EBITDA) and SRx's strength in Canada (stable and positive revenues, extensive infrastructure). Following the merger, the group has high growth potential (expected 2025 revenue three times higher than the sum of the previous companies, new business lines) but will need to demonstrate to the market that it can successfully integrate operations to translate that revenue into tangible profits. The current market valuation reflects the risks and dilution, as shown by SRXH's share price below the $1 threshold. The next few quarters will be crucial: the publication of the post-merger consolidated results and the execution of synergies will clarify whether SRx Health can realize the vision of a “global wellness company” outlined by management. Investors will be watching the company's ability to maintain its growth trajectory in both segments and improve margins as it moves toward net profitability. A clear communication plan and strategic focus will also be crucial to leverage the company's distinctive strengths without diluting their value. Ultimately, SRx Health (SRXH) represents a unique case of cross-pollination between the pet and healthcare sectors, with financial metrics to be rebuilt post-merger but with interesting market opportunities if it can consolidate its position and convince stakeholders of the sustainability of its new business model. Sources : Official SEC documents (10-K 2024 and 10-Q1 2025) and company press releases; d1io3yog0oux5.cloudfront.net; IR presentations and GlobeNewswire; globenewswire. com; d1io3yog0oux5.cloudfront.net; industry market data and financial websites (Yahoo Finance, Nasdaq, FMP) for quotes and comparisons; stockanalysis.com; nasdaq.com; databridgemarketresearch.com.
AMEX:SRXHLong
by J_B_
1
Life Time Opportunity Trade Setup NYSE:UNH Entry Price: $280 (at market open) Profit Target: $400 Stop Loss: $250 Risk-Reward Ratio: 4.3:1 Position Size: 1% of portfolio Why Bullish? UNH is trading near a 5-year low ($248.88) after a -50% drop in a month, driven by a DOJ Medicare fraud probe and CEO change. Despite the noise, analysts are bullish with 55 Buy ratings and a $445-$460 target, pointing to undervaluation (forward P/E ~10x). Institutional buying (Viking Global +12.5% stake) and a low VIX (17.83) support a potential rebound. Key Catalysts Technicals: Near 52-week low, RSI oversold, potential reversal. Fundamentals: $400B revenue, 15% EPS growth projected long-term. News: DOJ probe and suspended 2025 guidance weigh, but analysts see overreaction. Macro: VIX at 17.83 (stable), 10-year yields at 4.424% (headwind). Risks Ongoing DOJ investigation could escalate. Rising medical costs and volatile sentiment. Further downside if support at $250 breaks. Chart Notes UNH testing major support at $250-$270. Volume spikes on selling, but capitulation may signal a bottom. Watch for a break above $300 to confirm bullish momentum. Keep your long term vision Follow for the Best AI generated Signals on the market Ash.
NYSE:UNHLong
by AlphaSignals_ai
12
Harmonic Shark Pattern and Palantir's Stock CorrectionBased on harmonic analysis, specifically the Shark pattern, the price of Palantir (PLTR) stock may face a potential decline from the $129 mark. This projection hinges on the identification of a completed Shark pattern, indicating a possible reversal zone. Within this framework, the Fibonacci ratios of 0.88 and 1.138 are critical levels to observe. The 0.88 retracement level suggests a potential area for a first retest and possible bounce, while the 1.138 level represents the pattern's leading edge, indicating a possible reversal point after a more significant extension.
NASDAQ:PLTR
by SEYED98
CMS Lining Up for a Major Long-Term Breakout strong bullish structure forming on the weekly timeframe for CMS Energy Corp (CMS). This stock has been respecting a well-defined ascending channel since mid-2022, consistently bouncing from the lower trendline — as highlighted by the green arrows. ✅ Four confirmed touches on the lower trendline (2022, 2023, and multiple in 2024–2025) show strong buying interest on dips. 📉 Current pullback appears to be a healthy retest within the bullish channel — the label “RETEST FUTURE” marks the probable bounce area. 🧱 Horizontal resistance around $79.00 could turn into support after a clean breakout. 📊 Price projection path suggests higher highs toward the $100–$120 range by late 2026 if momentum continues. If CMS respects the trendline again and confirms a bounce, I'm targeting a multi-leg move toward the upper boundary of the channel. Tight stop loss below the lower trendline could offer great risk-reward ratio 🎯.
NYSE:CMSLong
by oTokyou
Netflix (NFLX) Share Price Reaches Record HighNetflix (NFLX) Share Price Reaches Record High According to the charts, Netflix (NFLX) shares have risen above $1,170 – the highest level in the company’s history. Since the start of 2025, the price of NFLX stock has increased by approximately 33%, while the S&P 500 index (US SPX 500 mini on FXOpen) remains close to its opening levels from 2 January. Why Is Netflix (NFLX) Performing Strongly? A month ago, we highlighted several factors contributing to NFLX’s outperformance relative to the broader stock market. Among them is the fact that Netflix does not offer tradable goods subject to tariffs in trade wars. As a result, the company could potentially benefit from an economic downturn if consumers spend more time at home. According to recent reports: → Netflix has announced that 94 million subscribers are now using its low-cost ad-supported plan – a figure more than a third higher than the 70 million reported in November. → The company also forecasts that advertising revenue will double this year. Technical Analysis of the NFLX Share Chart The share price continues to move within the upward channel (shown in blue) we identified previously. At the same time: → the price is currently near the upper boundary of this channel, which has repeatedly acted as resistance (as indicated by arrows); → the RSI indicator shows a potential bearish divergence. Under these conditions, a corrective move in Netflix’s stock price cannot be ruled out – for example, towards line Q or the channel median. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NASDAQ:NFLX
by FXOpen
1
Why it's time to take a closer look at Palantir stockWell well well, a good mystery starts with a whisper. For Palantir, it began in 2003, in the shadows of war-torn Iraq and Afghanistan. U.S. forces were struggling. Data was scattered. Decisions were delayed. Then came a company that promised to stitch the chaos together - to map the battlefield, spot terrorists, and maybe, just maybe, save lives! After two decades: Palantir is no longer just a software firm - it's a silent architect behind some of the West’s most mission-critical operations. 🕵️‍♂️ Mission? Not just to build technology. Not just to analyze data. But to influence life-and-death decisions - "Our product is used on occasion to kill people," their leadership says without blinking. 💼 Game? Winning Defense Department contracts - and commercial giants too. They've hired former Pentagon insiders, like Gregory Barbaccia and Shyam Sankar, and even political power players like Machalagh Carr, formerly Chief of Staff to House Speaker Kevin McCarthy. Play chess, not checkers? 💉 During the COVID-19 pandemic, Palantir stepped into the public health arena, building the infrastructure to track outbreaks and distribute vaccines for the U.S. government. They weren’t just responding - they were organizing the response. 🧠 And now? AI is their battlefield. In August 2024, they deepened ties with Microsoft, integrating Azure OpenAI with Palantir's AIP - but not just anywhere. In classified environments. The stakes? National security. The client? The U.S. government.
NASDAQ:PLTR
by Elias-Lo
Nike looking at a possible short term upsideNYSE:NKE Nike is looking at a possible mean reversion to the upside after long-term MACD is looking at a potential crossover of the signal line at the bottom and histogram is nearing to the zero line. Meanwhile, the Stochastic Oscillator has confirmed the oversold crossover, along side with the 23-period ROC rising above the zero line. Price action wise, the bullish engulfing candle at the gap resistance zone signal more buying pressure continuing. Besides that, the Ichimoku has shown two out of three bullish crossover. Short-term target is at 76.00
NYSE:NKELong
by William-trading
Baidu Accelerates Robotaxi Expansion and Opens the European DoorBy Ion Jauregui – Analyst at ActivTrades Baidu (NASDAQ: BIDU), the Chinese tech giant, is doubling down on autonomous vehicles through Apollo Go, its robotaxi platform. According to industry sources, the company is planning to expand into Europe, with Switzerland and Turkey as its first potential stops. Although Swiss Post has denied any official collaboration, Baidu has made clear its intention to open a Swiss office before the end of the year. This move could trigger a domino effect across Europe’s autonomous mobility ecosystem. Baidu not only leads the robotaxi market in China, but is also developing a globally scalable model. Europe, with its increasingly strict regulations on smart mobility and sustainability, could provide fertile ground to accelerate its deployment. This is an opportunity that Uber Technologies (NYSE: UBER) has already sensed. The U.S.-based company has signed strategic agreements with Asian firms such as WeRide, Pony.ai, and Momenta, aiming to roll out its own fleet of electric robotaxis in both Europe and the Middle East. At the same time, it is launching a new low-cost service in the U.S. called “Route Share,” a shared ride option that runs along the busiest routes every 20 minutes at half the price of UberX. The race to control the cities of the future isn’t limited to Uber and Baidu. Tesla (NASDAQ: TSLA) continues refining its Full Self-Driving (FSD) system, while Waymo, Google’s (Alphabet, NASDAQ: GOOGL) autonomous vehicle division, already operates driverless robotaxis in several U.S. cities and also has its eyes on Europe. The message is clear: the autonomous driving war has begun, and the battlefield is global. While distrust toward Chinese suppliers grows in Washington—evidenced by Hesai (NASDAQ: HSAI) being added to the U.S. blacklist—Europe is opening new paths for companies like Uber, Bolt, or Free Now to either collaborate or compete with tech giants such as Baidu, Tesla, or Google in the development of urban autonomous fleets. Baidu in Numbers As of now, Baidu has not yet released its Q1 2025 financial results. The company is scheduled to announce them on May 21, 2025. However, according to available estimates, Baidu is expected to report a net income of approximately CNY 206.52 billion for fiscal year 2025, which would mark a significant 791.24% increase compared to the CNY 23.17 billion recorded in 2024. In terms of revenue, Baidu is projected to reach around CNY 139.78 billion in 2025, up from CNY 133.13 billion the previous year. These figures reflect a notable improvement in the company’s profitability, likely driven by its focus on emerging technologies such as artificial intelligence and autonomous vehicles. For more detailed and updated information, it is recommended to consult Baidu’s official investor relations site after May 21, 2025, when the Q1 results will be published. Technical Analysis Since reaching its peak of $160.88 in 2023, Baidu’s stock has undergone a correction, dropping to a low of $73.58 in 2022, amid the onset of the U.S. tariff war. Currently, after the suspension of tariffs, the stock has rebounded to the $90 range, which corresponds to its current point of control, as trading volume has been concentrated around this price level. It is likely that, following the upcoming earnings report, the stock may surpass the $92.61 mark, which aligns with the 61.8% Fibonacci retracement level. However, to confirm a solid trend reversal, we would need to see a sustained upward crossover in moving averages—which has not yet occurred. So far, only a bullish crossover of the 50-day and 100-day moving averages was observed in Wednesday’s session. Investors should monitor whether this upward movement continues toward the secondary target of $96 during this summer quarter. Why Does This Matter to Investors? Baidu’s expansion into Europe could not only reshape the urban mobility landscape but also spark investment opportunities in software, hardware, LIDAR sensors, cybersecurity, and connected services. For companies like Uber, it also presents a chance to strengthen their leadership while reducing reliance on human drivers. Europe is looking ahead, and in that future, robotaxis are not science fiction—they’re strategy. ******************************************************************************************* The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and such should be considered a marketing communication. All information has been prepared by ActivTrades ("AT"). The information does not contain a record of AT's prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance is not reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acting on the information provided does so at their own risk.
NASDAQ:BIDULong
by ActivTrades
NVIDIA (NVDA) 4H Outlook – May 2025Price has recently shown multiple Breaks of Structure (BoS) to the upside, suggesting a potential shift in market sentiment. After a liquidity sweep of the prior low, price began forming higher highs and higher lows. Currently trading around $116.62, NVDA may revisit the demand zone between $107.99–$110 (highlighted in green) before resuming bullish momentum. If that level holds, we could see a continuation towards the $129.41 target zone, aligning with prior market structure and supply. This setup aligns with smart money concepts—monitor for confirmation at the demand zone before entering long.
NASDAQ:NVDALong
by Ttrade-With-Logic
Can $AMC come back to life again? NYSE:AMC is showing some good TA on the weekly and daily chart. We are visiting lows from the past, which reminds me of when I played NYSE:AMC and it visited the COVID lows. On both the Weekly and Daily we have the MACD in GREEN, RSI crossing MA which the weekly is showing downtrend being broke. Daily chart Is almost or is right on the 8 day crossing the 21 day EMA. Daily is also breaking the downtrend of ~$4.40 along with breaking the 100 day SMA. Holding VWAP form the low of $2.45 on 4/4/2025. NYSE:AMC Price as of 5/15/2025: $2.81 Need to see continuation out of the downtrend with volume Break the resistance level of $2.81 - $2.85, which has the 100 Day SMA around the $2.83 that needs to be cleared. Then $2.90 - $3.00 and we'll follow the Fib Levels and mark support/resistance levels as we go. This could get spicy so buckle up knuckleheads! NYSE:AMC Daily NYSE:AMC Weekly
NYSE:AMCLong
by Tillbob
5
Trade Setup Summary – ALNT/USD (30-Min Chart)!📈 Setup Type: Ascending Triangle Breakout (Bullish Continuation) ✅ Entry Zone: Around $32.72 – Confirmed breakout above resistance with clean structure 🔒 Stop-Loss (SL): Below $30.53 – Under rising trendline and strong horizontal support 🎯 Take Profit (TP) Targets: TP1: $35.44 – Key resistance zone (red line) TP2: $39.26 – Strong historical resistance (green line) 📊 Technical Highlights: Breakout from a tight ascending triangle pattern Supportive volume and strong price momentum Good risk-to-reward ratio – entry close to support, wide upside potential 📌 Summary: This is a long trade setup with bullish bias. Clean trendline structure and breakout confirmation make it ideal for continuation. Wait for volume follow-through to support move toward $35–39.
NASDAQ:ALNTLong
by ProfittoPath
Beazer Homes Stock Chart Fibonacci Analysis 051525Trading Idea 1) Find a FIBO slingshot 2) Check FIBO 61.80% level 3) Entry Point > 22/61.80% Chart time frame: D A) 15 min(1W-3M) B) 1 hr(3M-6M) C) 4 hr(6M-1year) D) 1 day(1-3years) Stock progress: A A) Keep rising over 61.80% resistance B) 61.80% resistance C) 61.80% support D) Hit the bottom E) Hit the top Stocks rise as they rise from support and fall from resistance. Our goal is to find a low support point and enter. It can be referred to as buying at the pullback point. The pullback point can be found with a Fibonacci extension of 61.80%. This is a step to find entry level. 1) Find a triangle (Fibonacci Speed Fan Line) that connects the high (resistance) and low (support) points of the stock in progress, where it is continuously expressed as a Slingshot, 2) and create a Fibonacci extension level for the first rising wave from the start point of slingshot pattern. When the current price goes over 61.80% level , that can be a good entry point, especially if the SMA 100 and 200 curves are gathered together at 61.80%, it is a very good entry point. As a great help, tradingview provides these Fibonacci speed fan lines and extension levels with ease. So if you use the Fibonacci fan line, the extension level, and the SMA 100/200 curve well, you can find an entry point for the stock market. At least you have to enter at this low point to avoid trading failure, and if you are skilled at entering this low point, with fibonacci6180 technique, your reading skill to chart will be greatly improved. If you want to do day trading, please set the time frame to 5 minutes or 15 minutes, and you will see many of the low point of rising stocks. If want to prefer long term range trading, you can set the time frame to 1 hr or 1 day.
NYSE:BZH
by fibonacci6180
Trade Setup Summary – ACHR/USD (30-Min Chart)!📈 Setup Type: Ascending Triangle Breakout (Bullish Continuation) ✅ Entry Zone: Around $12.19 (Breakout confirmation above horizontal resistance with volume) 🔒 Stop-Loss (SL): Below $11.32 (Below ascending trendline and recent structure support) 🎯 Take Profit (TP) Targets: TP1: $13.12 – First major resistance (red line) TP2: $14.36 – Previous swing high (green line / stronger resistance) 📊 Technical Highlights: Clear ascending triangle with bullish consolidation near breakout. Volume support and candle strength around breakout zone (yellow line). Good risk-to-reward structure: tight SL, wider potential upside. 📌 Summary: This is a long trade setup with bullish momentum. Watch for a sustained move above $12.19 to validate strength. Ideal for traders looking for momentum and breakout confirmation.
NYSE:ACHRLong
by ProfittoPath
2
Trade Setup Summary – CVI/USD (30-Min Chart)!📈 Setup Type: Ascending Triangle Breakout (Bullish Continuation) ✅ Entry Zone: Around $24.36 (Confirmed breakout above trendline and horizontal resistance) 🔒 Stop-Loss (SL): Below $23.45 (Under previous support and trendline base) 🎯 Take Profit (TP) Targets: TP1: $25.46 – Minor resistance level (horizontal red line) TP2: $27.00 – Major resistance (previous high zone, green line) 📊 Technical Highlights: Bullish breakout from ascending triangle with a clean trendline and volume increase. Consolidation near resistance now turned into support. Breakout candle formed above yellow horizontal line = confirmation zone. 📌 Summary: This is a long trade with a favorable risk-reward ratio. A stop-loss just below the structure minimizes risk, while upside targets offer a solid potential return. Ideal setup for momentum continuation.
NYSE:CVILong
by ProfittoPath
Trade Idea: BSX – Boston Scientific Corporation🔍 Technical Entry • Entry: $104.86 (market price as of latest close) • Stop: $96.61 (below recent swing low, ~–7.87%) • Target: $120.39 (analyst average target) ⸻ 🧪 Why BSX? • ✅ Strong Technicals: Breakout from tight consolidation above 21EMA & 50MA • ✅ Earnings Beast: 6 straight quarters of EPS beats; Q1 2025: +11.5% surprise • ✅ Raised Guidance: Management raised full-year targets across the board • ✅ Institutional Momentum: High analyst conviction — 25 “Strong Buy” ratings • ✅ Sector Tailwinds: Medical device demand + aging population + innovation ⸻ 📉 Risk Management • Keep position size aligned with 1R risk model (e.g. if risking $1,000, buy enough to trigger SL at $96.61) • Trail stop if price breaks above $108 with volume DISCLAIMER : The content and materials featured are for your information and education only and are not attended to address your particular personal requirements. The information does not constitute financial advice or recommendation and should not be considered as such. Risk Management is Your Shield! Always prioritise risk management. It’s your best defence against losses.
NYSE:BSXLong
by Gihanhemachandra
Tesla Inc. Stocks & Crypto: We Are All One!What one does, the rest follows. Tesla (TSLA) hit bottom in January 2023. It has been moving within a rising channel, higher highs and higher lows since. Volume was moving down until December 2024. The drop in volume was the preparation for a correction. Volume has been rising and 7-April 2025 produced the highest volume since February 2023. Here is the thing, when the highest buying came in February 2023, it was the start of this major bullish dynamic, the rising channel. Now volume starts to rise again after a major low (a higher low by the way). This means that we are set to experience another phase of growth, reaching new highs compared to December 2024 and in December TSLA produced its All-Time High. This means that the current bullish wave, brand new, will end in a new ATH in a matter of months. Isn't that great? Knowing that Tesla is growing and set to continue growing, we know that all related markets or those that have a positive correlation with this one will also grow; What one does, the rest follows. Thanks a lot for your continued support. Namaste.
NASDAQ:TSLALong
by MasterAnanda
1